Extension Trial Data Shows Cladribine Benefits Persist in RRMS Patients
The beneficial effects of Cladribine for relapsing-remitting multiple sclerosis (RRMS) patients have been demonstrated in a 120-week extension trial
AAN 2016 Multiple Sclerosis
Favorable Risk-Benefit Profile for Ozanimod in Relapsing Multiple Sclerosis
Ozanimod (RPC1063), an oral selective S1P receptor modulator currently in development, has shown efficacy in reducing relapse rates in relapsing multiple sclerosis.
Concomitant SSRIs Not Found to Affect Fingolimod-Associated Cardiac Events
For patients with relapsing-remitting Multiple Sclerosis (RRMS), concomitant use of selective serotonin-reuptake inhibitors (SSRIs) and fingolimod, does not affect cardiac outcomes related to initiation of fingolimod.
Laquinimod Tied to Reduced Relapses, Disability Progression in Some RRMS Patients
For relapse-remitting MS patients with expanded disability status scale (EDSS) scores of >3, once-daily laquinimod 0.6mg can reduce annualized relapse rates (ARR) and confirmed disability progression (CDP).
Interferon Does Not Up Antidepressant Use in MS Population
No correlation between interferon treatment and antidepressant use was observed in the multiple sclerosis (MS) population, a large-scale study presented at the 68th AAN Annual Meeting reported.
Interim Report Released on Real-World Safety of Fingolimod for Relapsing MS
An interim 4-year follow-up analysis of fingolimod (Gilenya) found the safety profile of the treatment to be consistent with the results of phase 3 clinical trials, researchers reported at the 68th Annual AAN Meeting.
Study Confirms Natalizumab Efficacy, Safety in Treating RRMS
Natalizumab use has been tied to a reduction in annual relapse rates (AAR) for patients with relapsing-remitting multiple sclerosis (RRMS).
Oral Propionate Demonstrates Beneficial Effects for Patients with MS
The beneficial effects of oral propionate, an approved food additive, have been demonstrated in humans for the first time, according to a study presented at the 68th Annual AAN Meeting.
Lipoic Acid May Provide Inexpensive Tx Option for Secondary Progressive MS
Lipoic acid is safe, well tolerated, and offers neuroprotection in patients with secondary progressive multiple sclerosis (MS), results from a “highly promising pilot study” presented at the 68th Annual AAN Meeting have shown.
Multiple Sclerosis Progression May Not be Biphasic or Have Uniform Trajectory
Patients with relapse-onset multiple sclerosis (MS) who have reached disease steps 3, 4, or 6 should still receive highly effective immunomodulatory therapy to mitigate disability accrual.
Want to read more?
Please login or register first to view this content.
